oral prostaglandin F receptor GCPR antagonist
to treat IPF, in vivo efficacy in fibrosis model
from ~3M cmpd cell-based HTS and opt.
J. Med. Chem., Oct. 22, 2020 issue
Bayer AG, Wuppertal, DE
BAY-6672
BAY-6672 (Bayer oral in vivo prostaglandin F receptor GCPR antagonist)